Back to results

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Primary Purpose

Lymphoma

Status

Completed

Phase

Phase 1

Locations

United States

Study Type

Interventional

Intervention

milatuzumab

veltuzumab

Correlative/Special Studies

Quantitative T-, B-, and NK cell subsets

Pharmacokinetics

Human Anti-Human Antibodies

veltuzumab and milatuzumab

About this trial

This is an interventional treatment trial for Lymphoma focused on measuring recurrent mantle cell lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma, recurrent marginal zone lymphoma, Waldenstrom macroglobulinemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Histologically confirmed B-cell non-Hodgkin lymphoma (NHL), including any of the following:
- Marginal zone lymphoma
- Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma)
- Follicular lymphoma
- Mantle cell lymphoma
Relapsed or refractory disease after ≥ 1 prior therapy
Patients with rituximab-refractory disease (defined as having less than a partial response to the prior rituximab-containing regimen) or rituximab-sensitive disease (defined as having a complete response or partial response to the last rituximab-containing regimen [provided it has been ≥ 3 months since the last dose of rituximab]) are eligible.
Age >18 years.
Eastern Cooperative Oncology Group (ECOG)performance status 0-2.
Patients must have normal organ and marrow function as defined below:
- Absolute neutrophil count ≥ 1000/μL
- Platelets ≥ 75,000/μL
- Total bilirubin ≤ 2.0 X institutional upper limit of normal
- AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional upper limit of normal
- Creatinine ≤ 2.0 mg/dL
Patients who have relapsed after stem cell transplant are eligible for this trial.
Patients with active Hepatitis B infection are not eligible.
Non-pregnant and non-nursing. Women of child bearing potential and men must agree to use contraception prior to study entry and for duration of study participation.
Must possess the ability to understand and the willingness to sign a written informed consent document.

Phase II

-Must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension >10 mm or in the case of Waldenstrom's macroglobulinemia, the presence of an IgM paraprotein level 2x the upper limit of normal.

Exclusion Criteria:

Must be recovered from all toxicities from prior therapy or radiation (excluding alopecia).
No known CNS lymphoma.
History of documented human anti-globulin antibodies.
No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations.
HIV-positive patients.
Pregnant women.
Patients with secondary malignancies with exception of non-melanomatous skin cancers.

Sites / Locations

Ohio State University Comprehensive Cancer Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Arm Label

Phase I

Phase II

Arm Description

Phase I portion of the study, a standard 3+3 dose escalation schema will be followed. Patients will receive veltuzumab IV weekly on day 1 for 4 doses and milatuzumab weekly on for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab alone on day 1 and milatuzumab alone on day 2 to prevent overlapping infusion reactions. Starting week 2, veltuzumab will be given on day 1 and milatuzumab will be given on day 4.

Patients will receive veltuzumab IV weekly for 4 doses and milatuzumab IV weekly on day 2 of week 1 and on day 4 of weeks 2-4 for 4 total doses during induction therapy. Patients may continue on therapy to receive extended induction therapy provided they do not experience significant toxicity or rapid disease progression during the initial 4 week induction.

Outcomes

Primary Outcome Measures

Dose Limiting Toxicity (DLT) for Phase I Patients

Dose-limiting toxicity was assessed during induction therapy for phase I.

Maximum Tolerated Dose (MTD)for Phase I Patients

Patients received a fixed dose of Veltuzumab IV 200 mg/m2 and Milatuzumab was dose escalated

Overall Objective Response Rate

Per International Response Criteria (Cheson JCO 2007) for target lesions and assessed by CT, MRI or PET: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses; Overall Response (OR) = CR + PR.

Secondary Outcome Measures

Progression-free Survival (PFS)

Progression is defined using International Response Criteria (Cheson JCO 2007), as a >= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or at least a 50% increase in the longest diameter of any single previously identified node more than 1 cm in its short axis, or the size of other lesions (eg, splenic or hepatic nodules), or the appearance of new lesions.

Fcγ-receptor Polymorphism Response to Treatment

The relationship between overall response rate (ORR) and Fcy receptor status. A two-sided chi-square test or exact test with α = 0.05 will be used to test the homogeneity of the ORR among the three genotypes.

Quantitative T-, B-, and NK-cell Subsets Using Flow Cytometry

Quantitative T-, B-, and NK- cell subsets will be assessed using flow cytometry to quantify the percentage and absolute number of cells expressing CD4, CD8, CD56, CD16, CD19, and CD20 at screening, after induction, and prior to the start of therapy on day 1 week 12, day 1 week 28, and then every 4 months for one year.

Access Pharmacokinetics Through AUC0-∞ (Area Under Curve)

Evaluation of pharmacokinetics (Pk) of veltuzumab and milatuzumab was performed for patients included in the trial. Statistically, descriptive data of PK parameters will be computed. Relationships between such parameters as dose and AUC, volume of distribution, clearance, and others will be evaluated, but be preliminary due to the small sample size.

Access Pharmacokinetics Through Cmax

Evaluation of pharmacokinetics of veltuzumab and milatuzumab was performed for patients included in the trial. Statistically, descriptive data of PK parameters will be computed. Relationships between such parameters as dose and AUC, volume of distribution, clearance, and others will be evaluated, but be preliminary due to the small sample size.

Monitor Human Anti-veltuzumab Antibodies and Human Anti-milatuzumab (HAHA)

Patients will be monitored for the development of human anti-veltuzumab antibodies and human anti-milatuzumab antibodies (HAHA).

Full Information

NCT ID

NCT00989586

First Posted

October 2, 2009

Last Updated

December 8, 2016

Sponsor

Beth Christian

Collaborators

Gilead Sciences

1. Study Identification

Unique Protocol Identification Number

NCT00989586

Brief Title

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Official Title

A Phase I/II Study of Veltuzumab (IMMU-106, hA20), a Humanized Anti-CD20 Monoclonal Antibody, Combined With Milatuzumab (IMMU-115, hLL1), a Humanized Anti-CD74 Monoclonal Antibody, in Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

Study Type

Interventional

2. Study Status

Record Verification Date

December 2016

Overall Recruitment Status

Completed

Study Start Date

September 2009 (undefined)

Primary Completion Date

April 2015 (Actual)

Study Completion Date

September 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor-Investigator

Name of the Sponsor

Beth Christian

Collaborators

Gilead Sciences

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

A phase I dose escalation study of veltuzumab and milatuzumab in relapsed and refractory B-cell NHL. The phase I study will be followed by a pilot phase II study.

Detailed Description

A phase I/II study of veltuzumab combined with milatuzumab in relapsed and refractory non-Hodgkin's lymphoma. Both agents are well-tolerated in early phase clinical testing with infusion reactions as the primary observed toxicity. Preclinical testing in vitro and in vivo have demonstrated single agent activity for both veltuzumab and milatuzumab. In mantle cell lymphoma cell lines and SCID mouse models, synergist effects were observed when milatuzumab was combined with rituximab. Veltuzumab has several advantages over rituximab including slower off-rates, shorter infusion times, higher potency, and improved therapeutic responses in animal models. Previous and ongoing clinical investigations support the concept of combining monoclonal antibodies in NHL.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Lymphoma

Keywords

recurrent mantle cell lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma, recurrent marginal zone lymphoma, Waldenstrom macroglobulinemia

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 1, Phase 2

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

Non-Randomized

Enrollment

35 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Phase I

Arm Type

Experimental

Arm Description

Arm Title

Phase II

Arm Type

Experimental

Arm Description

Intervention Type

Biological

Intervention Name(s)

milatuzumab

Other Intervention Name(s)

monoclonal antibody

Intervention Description

Patient will receive milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive milatuzumab on day 2. Starting in week 2, milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.

Intervention Type

Biological

Intervention Name(s)

veltuzumab

Other Intervention Name(s)

monoclonal antibody

Intervention Description

Patient will receive veltuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.

Intervention Type

Procedure

Intervention Name(s)

Correlative/Special Studies

Other Intervention Name(s)

blood samples

Intervention Description

To correlate Fcγ receptor polymorphisms with response to treatment with the combination of veltuzumab and milatuzumab. Whole blood will be collected pre-treatment on day 1.

Intervention Type

Procedure

Intervention Name(s)

Quantitative T-, B-, and NK cell subsets

Other Intervention Name(s)

blood samples

Intervention Description

Quantitative T-, B-, and NK- cell subsets will be assessed using flow cytometry to quantify the percentage and absolute number of cells expressing CD4, CD8, CD56, CD16, CD19, and CD20 pre-treatment on day 1, after induction (week 5, day 1), and prior to the start of therapy on day 1 week 12, day 1 week 36, and then every 4 months for one year.

Intervention Type

Procedure

Intervention Name(s)

Pharmacokinetics

Other Intervention Name(s)

blood samples

Intervention Description

To assess the pharmacokinetics of veltuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 1 of weeks 1, 2, 4, 12 and 36. One additional sample will be collected each of weeks 5 through 10 (sample may be collected any day during each of these weeks).

Intervention Type

Procedure

Intervention Name(s)

Pharmacokinetics

Other Intervention Name(s)

blood samples

Intervention Description

To assess the pharmacokinetics of milatuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 2 of week 1 and day 1 of weeks 2, 4, 12 and 36. Additional samples will be collected days 3 through 6 of week 1.

Intervention Type

Procedure

Intervention Name(s)

Human Anti-Human Antibodies

Other Intervention Name(s)

blood samples

Intervention Description

To monitor for the development of human anti-veltuzumab antibodies and human anti-milatuzumab antibodies (HAHA) in patients receiving treatment with veltuzumab and milatuzumab. Patients will be monitored for the development of HAHA at the following timepoints: pre-treatment on day 1 of week 1, pre-treatment on day 1 of week 4, pre-treatment on day 1 of week 12, and pre-treatment on day 1 of week 36.

Intervention Type

Biological

Intervention Name(s)

veltuzumab and milatuzumab

Other Intervention Name(s)

monoclonal antibody

Intervention Description

Patient will receive veltuzumab and milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab on day 1 and milatuzumab on day 2. Starting in week 2, veltuxumab will be given on day 1 and milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.

Primary Outcome Measure Information:

Title

Dose Limiting Toxicity (DLT) for Phase I Patients

Description

Dose-limiting toxicity was assessed during induction therapy for phase I.

Time Frame

up to 2 years

Title

Maximum Tolerated Dose (MTD)for Phase I Patients

Description

Patients received a fixed dose of Veltuzumab IV 200 mg/m2 and Milatuzumab was dose escalated

Time Frame

up to 2 years

Title

Overall Objective Response Rate

Description

Time Frame

Up to 2 years

Secondary Outcome Measure Information:

Title

Progression-free Survival (PFS)

Description

Time Frame

up to 2 years

Title

Fcγ-receptor Polymorphism Response to Treatment

Description

Time Frame

up to 2 years

Title

Quantitative T-, B-, and NK-cell Subsets Using Flow Cytometry

Description

Time Frame

up to 1 year

Title

Access Pharmacokinetics Through AUC0-∞ (Area Under Curve)

Description

Time Frame

0, 24, 48, 72, 96 and 120 hours post-does

Title

Access Pharmacokinetics Through Cmax

Description

Time Frame

0, 24, 48, 72, 96 and 120 hours post-dose

Title

Monitor Human Anti-veltuzumab Antibodies and Human Anti-milatuzumab (HAHA)

Description

Patients will be monitored for the development of human anti-veltuzumab antibodies and human anti-milatuzumab antibodies (HAHA).

Time Frame

up to 36 weeks

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Histologically confirmed B-cell non-Hodgkin lymphoma (NHL), including any of the following: Marginal zone lymphoma Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma) Follicular lymphoma Mantle cell lymphoma Relapsed or refractory disease after ≥ 1 prior therapy Patients with rituximab-refractory disease (defined as having less than a partial response to the prior rituximab-containing regimen) or rituximab-sensitive disease (defined as having a complete response or partial response to the last rituximab-containing regimen [provided it has been ≥ 3 months since the last dose of rituximab]) are eligible. Age >18 years. Eastern Cooperative Oncology Group (ECOG)performance status 0-2. Patients must have normal organ and marrow function as defined below: Absolute neutrophil count ≥ 1000/μL Platelets ≥ 75,000/μL Total bilirubin ≤ 2.0 X institutional upper limit of normal AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional upper limit of normal Creatinine ≤ 2.0 mg/dL Patients who have relapsed after stem cell transplant are eligible for this trial. Patients with active Hepatitis B infection are not eligible. Non-pregnant and non-nursing. Women of child bearing potential and men must agree to use contraception prior to study entry and for duration of study participation. Must possess the ability to understand and the willingness to sign a written informed consent document. Phase II -Must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension >10 mm or in the case of Waldenstrom's macroglobulinemia, the presence of an IgM paraprotein level 2x the upper limit of normal. Exclusion Criteria: Must be recovered from all toxicities from prior therapy or radiation (excluding alopecia). No known CNS lymphoma. History of documented human anti-globulin antibodies. No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations. HIV-positive patients. Pregnant women. Patients with secondary malignancies with exception of non-melanomatous skin cancers.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Beth Christian, MD

Organizational Affiliation

Ohio State University

Official's Role

Principal Investigator

Facility Information:

Facility Name

Ohio State University Comprehensive Cancer Center

City

Columbus

State/Province

Ohio

ZIP/Postal Code

43210

Country

United States

12. IPD Sharing Statement

Plan to Share IPD

Citations:

PubMed Identifier

25847298

Citation

Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2015 Jun;169(5):701-10. doi: 10.1111/bjh.13354. Epub 2015 Apr 7.

Results Reference

result

Links:

URL

http://cancer.osu.edu

Description

Jamesline

Learn more about this trial

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

We'll reach out to this number within 24 hrs